This thread is for updates about the ASCO 2012 meeting as it is going on.
If you are a myeloma patient, caregiver, or physician (including Beacon Medical Advisor) who is attending the ASCO meeting, and you would like to let the Beacon's readers know about what's going on at the meeting, this is the place to do it.
The Beacon team covering the meeting also will be using this thread to keep readers posted on what is going on during the meeting.
Please note that this thread is not intended to be a repository of links to other websites with ASCO coverage. Instead, we'd like this thread to be a one-stop source of information about what's going on at the meeting and people's impressions of the meeting.
Forums
Re: ASCO 2012 - Updates From The Meeting
The 2012 annual meeting of the American Society of Clinical Oncology kicked off today (Friday) in Chicago. Although there were a number of interesting poster and oral presentations, none were directly myeloma-related.
Thus, Saturday will be the first day for which The Beacon will be publishing updates on what is happening at the meeting.
This year, most ot the Beacon's reporting about the meeting will be in the form of news stories published on the site's front page. Initially, you'll be seeing mainly daily updates giving quick overviews of the key research being presented at the meeting. Later, there will be standalone articles on specific topics.
As the meeting proceeds, however, we'll be posting occasionally here with updates on what is going on that's related to multiple myeloma. We're not going to be doing blow-by-blow accounts of each presentation and poster; we're going to leave most of that sort of reporting to the news reports.
Instead, what you'll see here is quicker updates about what's happening and and what sort of impressions we have of the meeting so far.
Stay tuned!
Thus, Saturday will be the first day for which The Beacon will be publishing updates on what is happening at the meeting.
This year, most ot the Beacon's reporting about the meeting will be in the form of news stories published on the site's front page. Initially, you'll be seeing mainly daily updates giving quick overviews of the key research being presented at the meeting. Later, there will be standalone articles on specific topics.
As the meeting proceeds, however, we'll be posting occasionally here with updates on what is going on that's related to multiple myeloma. We're not going to be doing blow-by-blow accounts of each presentation and poster; we're going to leave most of that sort of reporting to the news reports.
Instead, what you'll see here is quicker updates about what's happening and and what sort of impressions we have of the meeting so far.
Stay tuned!
Re: ASCO 2012 - Updates From The Meeting
Good morning all,
It's a beautiful day today in Chicago and the second day of the ASCO meeting is off and running.
This morning, there is a poster session where a number of posters are being presented with results about potential new myeloma treatments, including pomalidomide, carfilzomib, and MLN9708. There are also results being presented about secondary cancers and low-dose (metronomic) therapy in patients in advanced myeloma.
Early this afternoon, there will be an educational session where three oral presentations will be presented on "controversies" in the treatment of myeloma.
It's a beautiful day today in Chicago and the second day of the ASCO meeting is off and running.
This morning, there is a poster session where a number of posters are being presented with results about potential new myeloma treatments, including pomalidomide, carfilzomib, and MLN9708. There are also results being presented about secondary cancers and low-dose (metronomic) therapy in patients in advanced myeloma.
Early this afternoon, there will be an educational session where three oral presentations will be presented on "controversies" in the treatment of myeloma.
-
Boris Simkovich - Name: Boris Simkovich
Founder
The Myeloma Beacon
Re: ASCO 2012 - Updates From The Meeting
We just published our first daily update for the ASCO meeting. It covers this morning's poster session. You can read it here:
https://myelomabeacon.org/news/2012/06/02/asco-2012-multiple-myeloma-update-day-two-poster-session/
https://myelomabeacon.org/news/2012/06/02/asco-2012-multiple-myeloma-update-day-two-poster-session/
Re: ASCO 2012 - Updates From The Meeting
Put this in the category of "batty" ASCO news ... While at the meeting this afternoon, I went out to a large outdoor terrace for some fresh air and a chance to soak up a nice view of Lake Michigan.
Just as I stepped out onto the terrace, I noticed what I first thought was a large, dark brown frog, crawling on the ground.
I looked at the animal closer, though, and it turned out to be ... a bat.
He didn't seem too healthy. Perhaps he flew into one of the large window panes by the terrace, or maybe he was just sick. In any case, he wasn't getting the whole "take off and fly away" thing together.
I was worried that a guard or custodian might come around and end the bat's day in a rather final way. So I coaxed him onto some of my papers and carted him off to some landscaping at the edge of the terrace.
He isn't likely to be bothered very much there. So, hopefully, he'll have a chance to recuperate and get back to being a healthy, happy bat.
Sorry I didn't take any pictures to document the whole saga. I was too preoccupied with figuring out what to do with the little guy before the options became -- how shall I say it? -- a lot more limited.
Just as I stepped out onto the terrace, I noticed what I first thought was a large, dark brown frog, crawling on the ground.
I looked at the animal closer, though, and it turned out to be ... a bat.
He didn't seem too healthy. Perhaps he flew into one of the large window panes by the terrace, or maybe he was just sick. In any case, he wasn't getting the whole "take off and fly away" thing together.
I was worried that a guard or custodian might come around and end the bat's day in a rather final way. So I coaxed him onto some of my papers and carted him off to some landscaping at the edge of the terrace.
He isn't likely to be bothered very much there. So, hopefully, he'll have a chance to recuperate and get back to being a healthy, happy bat.
Sorry I didn't take any pictures to document the whole saga. I was too preoccupied with figuring out what to do with the little guy before the options became -- how shall I say it? -- a lot more limited.
-
Boris Simkovich - Name: Boris Simkovich
Founder
The Myeloma Beacon
Re: ASCO 2012 - Updates From The Meeting
Good deed, Boris, but also good you didn't make physical contact with it. If the bat was sick there is always the chance it carried rabies. Bats are, perhaps, the most notorious carriers of rabies worldwide. Hopefully, that was not the case with the Chicago critter. Are you going to cover Jakubowiak and the CRD trial for newly diagnosed patients...looking forward to that. Thanks. Terry
-
terryl1 - Name: Terry
- Who do you know with myeloma?: self
- When were you/they diagnosed?: August 10, 2011
- Age at diagnosis: 49
Re: ASCO 2012 - Updates From The Meeting
Hi Terry,
I was very careful not to make any contact with the bat. I've heard about the risk of rabies associated with bats, so I first watched the bat for a few minutes to make sure it wasn't showing any signs of the disease. I also was extra careful as I was attempting to move it that I wasn't caught off-guard by any sudden movement it might make in the direction of my fingers or wrists.
I did learn, by the way, that bats hiss like cats do when they're upset about something.
Yes, we'll be covering the oral presentations about carfilzomib that are going to be presented tomorrow morning. Look for the latest data from the studies in the daily updates for tomorrow's presentations.
Thanks!
I was very careful not to make any contact with the bat. I've heard about the risk of rabies associated with bats, so I first watched the bat for a few minutes to make sure it wasn't showing any signs of the disease. I also was extra careful as I was attempting to move it that I wasn't caught off-guard by any sudden movement it might make in the direction of my fingers or wrists.
I did learn, by the way, that bats hiss like cats do when they're upset about something.
Yes, we'll be covering the oral presentations about carfilzomib that are going to be presented tomorrow morning. Look for the latest data from the studies in the daily updates for tomorrow's presentations.
Thanks!
-
Boris Simkovich - Name: Boris Simkovich
Founder
The Myeloma Beacon
Re: ASCO 2012 - Updates From The Meeting
Wow Boris!!
A bat?! You are very courageous and compassionate. I would have been terrified and thinking all types of thoughts similiar to Terry's..rabies..rare viral contagion....I am impressed that you acted alone. I would have been calling the animal control center...and exited that terrance lickety split.
It is very odd to see bats during the day. I can see why you thought it could have flown into window or building. Over a billion birds are killed yearly flying into windows.
Are you going to cover Dr. Landgren's presentation?
Enjoy the rest of ASCO 2012 and beautiful Lake Michigan.
A bat?! You are very courageous and compassionate. I would have been terrified and thinking all types of thoughts similiar to Terry's..rabies..rare viral contagion....I am impressed that you acted alone. I would have been calling the animal control center...and exited that terrance lickety split.
It is very odd to see bats during the day. I can see why you thought it could have flown into window or building. Over a billion birds are killed yearly flying into windows.
Are you going to cover Dr. Landgren's presentation?
Enjoy the rest of ASCO 2012 and beautiful Lake Michigan.
-
suzierose - Name: suzierose
- When were you/they diagnosed?: 2 sept 2011
Re: ASCO 2012 - Updates From The Meeting
I just got back from today's morning session of myeloma-related oral presentations.
I now know what it's like to try to drink from a fire hose. There were nine presentations summarizing results of different research studies, with three additional presentations summarizing and discussing the other presentations.
We will be getting out news articles about the presentations later today.
In the meantime, let me share with you some quick impressions.
First, there were three presentations related to carfilzomib. The data for the drug certainly look good on the surface, and it's clear that carfilzomib has less peripheral neuropathy than IV Velcade dosed more frequently than once a week. However, a review presentation by Dr. Orlowski of MD Anderson pointed out that one has to dissect the data carefully before jumping to conclusions about carfilzomib's efficacy versus Velcade. (Many people assume carfilzomib is more effective than Velcade; Dr. Orlowski's presentation suggests that this assumption often rests on comparisons that aren't really in the "apple-to-apple" category.)
Second, the data for another drug in the same class as Velcade -- MLN9708 -- also suggest the drug has efficacy similar to Velcade with a better side effect profile than IV Velcade .
Third, it doesn't look like obatoclax is going to go anywhere anytime soon in terms of further development as an anti-myeloma agent. It had A LOT of toxicity in its initial clinical trial.
Fourth, the results for Treanda and panobinostat in combination with other agents in relapsed and refractory myeloma patients were interesting, but not really compelling.
Fifth, the results for pomalidomide in a patient population with very advanced myeloma were interesting not just because of the activity the drug showed, but also how it didn't seem to matter whether the patients had been previously treated with either Velcade, Revlimid, or both.
That's the quick rundown from this morning. As I said, look for more detailed summaries in news articles later today.
I now know what it's like to try to drink from a fire hose.
There were nine presentations summarizing results of different research studies, with three additional presentations summarizing and discussing the other presentations.We will be getting out news articles about the presentations later today.
In the meantime, let me share with you some quick impressions.
First, there were three presentations related to carfilzomib. The data for the drug certainly look good on the surface, and it's clear that carfilzomib has less peripheral neuropathy than IV Velcade dosed more frequently than once a week. However, a review presentation by Dr. Orlowski of MD Anderson pointed out that one has to dissect the data carefully before jumping to conclusions about carfilzomib's efficacy versus Velcade. (Many people assume carfilzomib is more effective than Velcade; Dr. Orlowski's presentation suggests that this assumption often rests on comparisons that aren't really in the "apple-to-apple" category.)
Second, the data for another drug in the same class as Velcade -- MLN9708 -- also suggest the drug has efficacy similar to Velcade with a better side effect profile than IV Velcade .
Third, it doesn't look like obatoclax is going to go anywhere anytime soon in terms of further development as an anti-myeloma agent. It had A LOT of toxicity in its initial clinical trial.
Fourth, the results for Treanda and panobinostat in combination with other agents in relapsed and refractory myeloma patients were interesting, but not really compelling.
Fifth, the results for pomalidomide in a patient population with very advanced myeloma were interesting not just because of the activity the drug showed, but also how it didn't seem to matter whether the patients had been previously treated with either Velcade, Revlimid, or both.
That's the quick rundown from this morning. As I said, look for more detailed summaries in news articles later today.
-
Boris Simkovich - Name: Boris Simkovich
Founder
The Myeloma Beacon
Re: ASCO 2012 - Updates From The Meeting
Hi Suzierose,
Were you referring to this abstract:
A prospective clinical study evaluating current models for risk of progression from smoldering multiple myeloma (SMM) to multiple myeloma (multiple myeloma).
http://abstract.asco.org/AbstView_114_93002.html
We'll be covering it in one of Monday's updates.
Were you referring to this abstract:
A prospective clinical study evaluating current models for risk of progression from smoldering multiple myeloma (SMM) to multiple myeloma (multiple myeloma).
http://abstract.asco.org/AbstView_114_93002.html
We'll be covering it in one of Monday's updates.
-
Julie Shilane - Name: Julie Shilane, Beacon Staff
26 posts
• Page 1 of 3 • 1, 2, 3